Citations 3
Body mass index and mortality in patients with pancreatic cancer: A systematic review and meta-analysis of observational studies.
Arora, Nivedita , Sen, Shiraj, Naina, Harris, Singh, Siddharth , Gupta, Arjun , Majumder, Kaustav, Singh, Preet Paul
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15293-e15293
Effect of premorbid body mass index on mortality in patients with lung cancer: A systematic review and meta-analysis.
Arora, Nivedita , Singh, Siddharth , Johnson, David H. , Gupta, Arjun , Majumder, Kaustav, Mayo, Helen , Singh, Preet Paul , Halm, Ethan A.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8523-8523
Incidence and outcomes of hospitalized patients with gastrointestinal malignancies and Clostridium difficile infection: A nationwide analysis.
Arora, Nivedita , Frank, Ryan D. , Beg, Muhammad S., Pardi, Darrell S. , Johnson, David H. , Khanna, Sahil , Gupta, Arjun , Tariq, Raseen
Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 704-704
10.1200/jco.2017.35.4_suppl.704
704 Background: Inpatients with gastrointestinal (GI) malignancies are at a high risk for Clostridium difficile infection (CDI) but the impact of CDI on outcomes in these patients needs elucidation. We analyzed the incidence of CDI and its impact on outcomes in GI cancer patients using the National Hospital Discharge Survey (NHDS) database from 2001 - 2010. Methods: NHDS collects clinical information on patients dismissed from non-Federal short-stay United States hospitals. Demographics, diagnoses (GI malignancies, CDI and comorbidities), length of stay (LOS), and dismissal information were abstracted using ICD-9 diagnosis and procedure codes. Weighted analyses were performed using SAS version 9.4. Results: Of an estimated 317.9 million unique hospitalizations; 4.6 million had a diagnosis of a GI malignancy (1.4%); median age 68 years, 46.1% female. CDI was more common in patients with GI malignancies compared to patients with no GI malignancy (1.05% vs 0.69%, aOR 1.16, 95% CI 1.15- 1.17, p < 0.0001). There was a significant increase in CDI incidence in GI cancer patients over the 10-year study period (72.7 in 2001-2002 to 109.1 in 2009-2010, per 10,000 discharges, p < 0001). In multivariable analysis, compared to GI cancer patients without CDI, GI cancer patients with CDI had a longer mean LOS (3.94 more days, 95% CI 3.31-4.56) and dismissal to a care facility (adjusted OR, 1.75; 95% CI, 1.71-1.79), but lower all-cause in-hospital mortality (adjusted OR, 0.76; 95% CI, 0.74-0.79), all p < 0.0001 Conclusions: In this national database of hospitalized patients, an increasing incidence of CDI in patients with GI malignancies was noted over the study period. CDI prolonged hospitalization, and was associated with increased dismissal to a care-facility. Lower rates of in-hospital mortality may represent early diagnosis due to vigilance or a milder form of CDI. Despite increased attention over the last few decades, CDI remained a serious infection in GI cancer patients, and merits appropriate prevention, management and follow-up.